The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO Italy 2020 | Novel approaches to PV and ET
Alessandro Lucchesi, MD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses novel therapies for polycythemia vera (PV) and essential thrombocythemia (ET) including ropeginteferon, an interferon that has been shown to control hematocrit levels in PV as evaluated in the CYTO-PV study. Dr Lucchesi outlines unmet clinical needs in this patient population including controlling the rate of thrombosis and reducing transformation into severe disease. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
